Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Bicara Therapeutics Inc.

BCAX · Nasdaq · CIK 0002023658 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

33 Form 4 transaction lines observed in the same window
21 sales · 12 option, withholding, award, gift or other lines

Last qualifying purchase2026-02-26 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M. · $4.8M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Cohlhepp RyanPresident, COO & Interim CEO
○▼○▼▼○▼○▼
Hyep IvanChief Financial Officer
○▼○▼○▼○▼
Mazumdar ClaireChief Executive Officer
○▼○▼○▼
Raben DavidChief Medical Officer
○▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-02-26 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M..

Recent Form 4 activity

1Purchases
57Sales
47Other Form 4 lines
37SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING21 sale line(s) · context only
OTHER12 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-19.9%
3M
-36.5%
6M
-26.4%
12M
+1.8%

Volatility & liquidity

Volatility
73.7%
Beta
—
Avg daily value
USD 11.7M

Valuation

Market cap
USD 1.2B
P/E
—

Fundamentals

Profit margin
—
ROE
-34.4%
Industry
Biotechnology

Market data

Price data up to: 2026-10-15 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
10,693,490
Previous report
11,191,724
Avg daily volume
753,208
Days to cover
14.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-02-26Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M.Purchase (P)Common Stock300,000USD 16.00USD 4,800,000SEC filing ↗
2024-09-17DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt V, L.P.; Deerfield Private Design Fund V, L.P.; Flynn James EPurchase (P)Common Stock35,000USD 18.00USD 630,000SEC filing ↗
2024-09-16Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Shah Rajeev M.Purchase (P)Common Stock1,833,000USD 18.00USD 32,994,000SEC filing ↗

Form 4 evidence

105 transaction lines in the latest 365-day window; 158 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08Cohlhepp RyanSale (S)Common Stock17,500USD 22.90USD 400,747SEC filing ↗
2026-09-08Cohlhepp RyanOption exercise / conversion (M)Common Stock17,500USD 3.79USD 66,325SEC filing ↗
2026-08-10Mazumdar ClaireSale (S)Common Stock10,000USD 27.98USD 279,800SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08Cohlhepp RyanSale (S)Common Stock17,500USD 22.90USD 400,747SEC filing ↗
2026-09-08Cohlhepp RyanOption exercise / conversion (M)Common Stock17,500USD 3.79USD 66,325SEC filing ↗
2026-08-10Mazumdar ClaireSale (S)Common Stock10,000USD 27.98USD 279,800SEC filing ↗
2026-08-10Mazumdar ClaireOption exercise / conversion (M)Common Stock10,000USD 3.79USD 37,900SEC filing ↗
2026-08-10Hyep IvanSale (S)Common Stock12,500USD 27.97USD 349,625SEC filing ↗
2026-08-10Hyep IvanOption exercise / conversion (M)Common Stock12,500USD 3.79USD 47,375SEC filing ↗
2026-08-10Cohlhepp RyanSale (S)Common Stock18,750USD 27.98USD 524,625SEC filing ↗
2026-08-10Cohlhepp RyanOption exercise / conversion (M)Common Stock18,750USD 3.79USD 71,062SEC filing ↗
2026-07-10Mazumdar ClaireSale (S)Common Stock10,000USD 28.42USD 284,235SEC filing ↗
2026-07-10Mazumdar ClaireOption exercise / conversion (M)Common Stock10,000USD 3.79USD 37,900SEC filing ↗
2026-07-09Cohlhepp RyanSale (S)Common Stock536USD 29.00USD 15,544SEC filing ↗
2026-07-08Hyep IvanSale (S)Common Stock28,000USD 28.84USD 807,603SEC filing ↗
2026-07-08Hyep IvanOption exercise / conversion (M)Common Stock12,500USD 3.79USD 47,375SEC filing ↗
2026-07-08Cohlhepp RyanSale (S)Common Stock28,214USD 28.98USD 817,622SEC filing ↗
2026-07-08Cohlhepp RyanOption exercise / conversion (M)Common Stock18,750USD 3.79USD 71,062SEC filing ↗
2026-05-21Hyep IvanSale (S)Common Stock9,200USD 20.42USD 187,864SEC filing ↗
2026-05-21Hyep IvanOption exercise / conversion (M)Common Stock9,200USD 3.79USD 34,868SEC filing ↗
2026-05-18Mazumdar ClaireSale (S)Common Stock15,000USD 20.04USD 300,561SEC filing ↗
2026-05-18Mazumdar ClaireOption exercise / conversion (M)Common Stock15,000USD 3.79USD 56,850SEC filing ↗
2026-05-15Cohlhepp RyanSale (S)Common Stock12,500USD 20.29USD 253,625SEC filing ↗
2026-05-15Cohlhepp RyanOption exercise / conversion (M)Common Stock8,000USD 3.79USD 30,320SEC filing ↗
2026-04-27Raben DavidSale (S)Common Stock5,500USD 22.88USD 125,840SEC filing ↗
2026-04-27Raben DavidOption exercise / conversion (M)Common Stock5,500USD 3.79USD 20,845SEC filing ↗
2026-04-21Hyep IvanSale (S)Common Stock9,200USD 23.00USD 211,600SEC filing ↗
2026-04-21Hyep IvanOption exercise / conversion (M)Common Stock9,200USD 3.79USD 34,868SEC filing ↗
2026-04-20Mazumdar ClaireSale (S)Common Stock15,000USD 23.61USD 354,150SEC filing ↗
2026-04-20Mazumdar ClaireOption exercise / conversion (M)Common Stock15,000USD 3.79USD 56,850SEC filing ↗
2026-04-16Mazumdar ClaireOption exercise / conversion (M)Common Stock22,760USD 4.54USD 103,360SEC filing ↗
2026-04-15Cohlhepp RyanSale (S)Common Stock12,500USD 23.01USD 287,625SEC filing ↗
2026-04-15Cohlhepp RyanOption exercise / conversion (M)Common Stock8,000USD 3.79USD 30,320SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerBCAX
CIK0002023658
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history158 transaction lines from 2024-09-16 to 2026-09-08
4 P purchase lines · 76 S sale lines · 78 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.